Guangzhou Ailalun Biotechnology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Guangzhou Ailalun Biotechnology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include IRALUN. The owner is based in Guangzhou, Guangdong.

Room 103, Building C, 228 Creative Park

No. 20, Xiaogang Huayuan RD, Baiyun DIST

Guangzhou, Guangdong 510000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

IRALUN
IRALUN
Registered 2025

Trademark Classifications

Guangzhou Ailalun Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Guangzhou Ailalun Biotechnology Co., Ltd. have?

Guangzhou Ailalun Biotechnology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Guangzhou Ailalun Biotechnology Co., Ltd. file in?

Guangzhou Ailalun Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Guangzhou Ailalun Biotechnology Co., Ltd.'s most well-known trademarks?

Guangzhou Ailalun Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as IRALUN. These are among 1 currently registered trademark in the portfolio.

What is Guangzhou Ailalun Biotechnology Co., Ltd.'s trademark registration success rate?

Guangzhou Ailalun Biotechnology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.